on Laxxon Medical
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Laxxon Medical, a US-based pharma-technology company, revealed plans to demonstrate its innovative LXM.2 asset at the BIO International Convention scheduled for June 3-6, 2024 in San Diego. The company is focusing on utilizing its novel 3D printing technology, SPID®, for this upcoming presentation.
The BIO International Convention, recognized as the world's largest biotech event, draws over 20,000 industry leaders annually, offering extensive networking prospects and opportunities for new partnerships.
LXM.2, designed as a once-a-day oral treatment for weight loss, integrates a GLP-1 agonist with a permeation enhancer via SPID® to enhance bioavailability. Laxxon aims to expedite LXM.2's development through the 505(b)2 pathway and seeks collaboration for out-licensing or co-development at the event.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Laxxon Medical news